Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Adagene reported a cash position of $127.9 million as of June 30, 2026, providing a runway into late 2028, while recognizing $1.6 million in revenue from collaboration milestones. Interim data from a Phase 1b/2 study in first-line hepatocellular carcinoma showed a 66.7% overall response rate for the muzastotug triplet, significantly outperforming the 32.5% rate in the control arm.
Key figures
- Revenue
- $1.6 million
- Runway
- late 2028
- Rd expenses
- $14.0 million
- Cash balance
- $127.9 million
- Net loss gaap
- $16.4 million
- Hcc orr triplet
- 66.7%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.